Current Treatment and Future Options of Ischemic Stroke

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Clinical Neurology".

Deadline for manuscript submissions: 25 October 2025 | Viewed by 826

Special Issue Editors


E-Mail
Guest Editor
Department of Biochemistry, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
Interests: neuroinflammation; oxidative stress; metabolic syndrome; stroke; multiple sclerosis

E-Mail Website
Guest Editor
Neuropsychiatry Hospital of Craiova, University of Medicine and Pharmacy of Craiova, Craiova, Romania
Interests: clinical stroke research; neurovascular disorders; stroke treatment strategies

Special Issue Information

Dear Colleagues,

Ischemic stroke remains a leading cause of mortality and long-term disability worldwide, necessitating continuous advancements in both acute management and long-term care. While current therapeutic strategies, such as intravenous thrombolysis and endovascular thrombectomy, have significantly improved patient outcomes, there is still a need for optimization in patient selection, treatment timing, and post-stroke recovery.

This Special Issue aims to explore recent advances and future directions in ischemic stroke treatment, including novel pharmacological approaches, neuroprotection strategies, rehabilitation techniques, and the role of precision medicine. Additionally, we invite research on emerging biomarkers, artificial intelligence in stroke prediction and management, and innovative therapeutic targets such as extracellular vesicles, stem cell therapy, and inflammation-modulating agents.

We welcome original research, systematic reviews, and clinical studies that provide insights into optimizing current treatment paradigms and shaping the future of ischemic stroke management. Our goal is to bring together leading experts and researchers to foster collaboration and drive progress in stroke care.

Prof. Dr. Raluca Elena Sandu
Prof. Dr. Carmen Valeria Albu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

 

Keywords

  • ischemic stroke
  • stroke
  • neuroinflammation
  • cerebral ischemia
  • thrombolysis
  • neuroprotection
  • rehabilitation strate-gies
  • stroke biomarkers
  • extracellular vesicles
  • stem cell therapy
  • post-stroke recovery
  • cerebral ischemia
  • advanced imaging in stroke
  • personalized stroke treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

22 pages, 4837 KiB  
Systematic Review
Safety and Efficacy of Stem Cell Therapy in Ischemic Stroke: A Comprehensive Systematic Review and Meta-Analysis
by Abdulrahim Saleh Alrasheed, Tala Abdullah Aljahdali, Israa Aqeel Alghafli, Ghadeer Aqeel Alghafli, Majd Fouad Almuslim, Noor Mohammad AlMohish and Majed Mohammad Alabdali
J. Clin. Med. 2025, 14(6), 2118; https://doi.org/10.3390/jcm14062118 - 20 Mar 2025
Viewed by 896
Abstract
Background: Although recent advancements in ischemic stroke management have reduced associated mortality rates, there remains a pressing need for more reliable, efficacious, and well-tolerated therapeutic approaches due to the narrow therapeutic window of current treatment approaches. The current meta-analysis sought to evaluate the [...] Read more.
Background: Although recent advancements in ischemic stroke management have reduced associated mortality rates, there remains a pressing need for more reliable, efficacious, and well-tolerated therapeutic approaches due to the narrow therapeutic window of current treatment approaches. The current meta-analysis sought to evaluate the safety and efficacy of stem cell-based therapeutic options for patients with ischemic stroke. Methods: PubMed, Web of Science, and Cochrane library databases were searched to retrieve randomized controlled trials (RCTs) evaluating the efficacy and safety of stem cell therapy (SCT) in ischemic stroke patients. Key outcomes included the National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), Barthel Index (BI), Fugl–Meyer Assessment (FMA), infarct size, and safety profile. The random effects model with the continuous method was used to calculate the pooled effect size in Review Manager 5.4.1, and subgroup analyses were performed based on demographics, stroke duration, and SCT delivery protocols. Results: A total of 18 RCTs involving 1026 patients were analyzed, with 538 in the treatment group and 488 in the control group. The mean change in NIHSS score was comparable between groups [MD = −0.80; 95% CI: −2.25, 0.65, p < 0.0001]. However, SCT showed better outcomes in mRS [MD = −0.56; 95% CI: −0.76, −0.35, p = 0.30] and BI scores [MD = 12.00; 95% CI: 4.00, 20.00, p = 0.007]. Additionally, the mean change in FMA score was significantly greater with SCT [MD = 18.16; 95% CI: 6.58, 29.75, p = 0.03]. The mean change in infarct volume also favored stem cell therapy [MD = 8.89; 95% CI: −5.34, 23.12, p = 0.08]. The safety profile was favorable, with adverse event rates comparable to or lower than controls. Conclusions: SCT offers a safe and effective approach to improving functional outcomes in stroke patients, particularly with early intervention. These findings highlight the potential of SCT in ischemic stroke rehabilitation while underscoring the need for standardized protocols and long-term safety evaluation. Full article
(This article belongs to the Special Issue Current Treatment and Future Options of Ischemic Stroke)
Show Figures

Figure 1

Back to TopTop